Literature DB >> 15690977

Formation and structure of transplantable tissue constructs generated in simulated microgravity from Sertoli cells and neuron precursors.

Don F Cameron1, J J Hushen, L Colina, J Mallery, A Willing, P R Sanberg, Samuel Saporta.   

Abstract

Cell transplantation therapy for Parkinson's disease (PD) has received much attention as a potential treatment protocol for this neurodegenerative condition. Although there have been promising successes with this approach, it remains problematic, especially regarding the inability to provide immediate trophic support to the newly grafted cells and the inability to prevent acute and/or long-term graft rejection by the host. To address these issues of cell graftability, we have created a novel tissue construct from isolated rat Sertoli cells (SC) and the NTerra-2 immortalized human neuron precursor cell line (NT2) utilizing NASA-developed simulated microgravity technology. The two cell types were cocultured at a 1:4 (SC/NT2) ratio in the High Aspect Rotating Vessel (HARV) biochamber for 3 days, after which a disc-shaped aggregate (1-4 mm diameter) was formed. Sertoli neuron aggregated cells (SNAC) were collected by gravity sedimentation and processed either for light and electron microscopy or for fluorescent immunocytochemistry. Intra-SNAC clusters of SC and NT2 cells were identified by anti-human mitochondrial protein (huMT--specific for NT2 cells) and cholera toxin subunit B (CTb--specific for SC). There was little evidence of cell death throughout the aggregate and the absence of central necrosis, as might be expected in such a large aggregate in vitro. Ultrastructurally, SC did not express junctional modifications with NT2 cells nor with adjacent SC as is typical of SC in vivo and, in some protocols, in vitro. NT2 cells, however, showed distinct intercellular junction-like densities with adjacent NT2 cells, often defining canaliculi-like channels between the microvillus borders of the cells. The results show that the use of simulated microgravity coculture provides a culture environment suitable for the formation of a unique and viable Sertoli-NT2 (i.e., SNAC) tissue construct displaying intra-aggregate cellular organization. The structural integration of SC with NT2 cells provides a novel transplantable tissue source, which can be tested to determine if SC will suppress rejection of the grafted NT2 cells and provide for their short- and long-term trophic support in situ in the treatment of experimental PD.

Entities:  

Keywords:  NASA Discipline Cell Biotechnology; Non-NASA Center

Mesh:

Substances:

Year:  2004        PMID: 15690977     DOI: 10.3727/000000004783983431

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  5 in total

1.  Tissue engineering of endothelial cells and the immune response.

Authors:  H Methe; E R Edelman
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

2.  The role of connexins in the differentiation of NT2 cells in Sertoli-NT2 cell tissue constructs grown in the rotating wall bioreactor.

Authors:  R Shamekh; D F Cameron; A E Willing; S Saporta
Journal:  Exp Brain Res       Date:  2005-11-19       Impact factor: 1.972

3.  Effects of Sertoli cell-conditioned medium on ventral midbrain neural stem cells: a preliminary report.

Authors:  Rania Shamekh; Samuel Saporta; Don F Cameron; Alison E Willing; Cindy D Sanberg; Karl Johe; P R Sanberg
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

Review 4.  The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Authors:  Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2012-04-11       Impact factor: 4.077

5.  Hypergravity stimulation enhances PC12 neuron-like cell differentiation.

Authors:  Giada Graziana Genchi; Francesca Cialdai; Monica Monici; Barbara Mazzolai; Virgilio Mattoli; Gianni Ciofani
Journal:  Biomed Res Int       Date:  2015-02-16       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.